GlassScriptPhysician profile
William C Holvik
NPI 1346225364
$16,370.08
in general payments reported to CMS, 2019-2025
63 companies · $1,816 in 2025
The $1,816 reported for 2025 was more than what 94% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,524 · 2020: $1,645 · 2021: $2,828 · 2022: $2,923 · 2023: $3,306 · 2024: $2,328 · 2025: $1,816.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,362 · Education: $88.77.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,362.05 |
| Education | $88.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,594.52 | 2019-2025 | |
| Novo Nordisk INC | $1,366.83 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Lilly USA, LLC | $1,331.54 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $1,214.23 | 2019-2025 | Farxiga, Breztri, Evusheld |
| Takeda Pharmaceuticals U.S.A., INC. | $1,053.13 | 2019-2024 | Trintellix |
| Otsuka America Pharmaceutical, INC. | $949.86 | 2020-2025 | Rexulti |
| Corcept Therapeutics | $847.41 | 2020-2023 | Korlym |
| Amgen INC. | $785.68 | 2019-2025 | Repatha, Otezla, Prolia |
| Pfizer INC. | $676.37 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $572.21 | 2019-2025 | Jardiance |
| Axsome Therapeutics, INC. | $551.72 | 2022-2025 | Auvelity, Sunosi |
| Allergan, INC. | $496.33 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $413.62 | 2021-2023 | |
| Antares Pharma, INC. | $407.60 | 2022-2025 | Xyosted, Tlando, Nocdurna |
| Biohaven Pharmaceutical Holding Company LTD. | $387.89 | 2022 |
Show all 63 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $373.33 | 2021-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Merck Sharp & Dohme LLC | $360.18 | 2019-2025 | Capvaxive, Gardasil 9, Gardasil |
| Astellas Pharma US INC | $280.93 | 2019-2025 | Veozah |
| Janssen Pharmaceuticals, INC | $200.47 | 2021-2023 | Xarelto |
| Lundbeck LLC | $191.39 | 2021-2024 | Vyepti |
| Biohaven Pharmaceuticals, INC. | $164.07 | 2020-2021 | |
| Amarin Pharma, INC. | $154.14 | 2020-2021 | |
| Mylan Specialty L.P. | $118.92 | 2019-2023 | Yupelri, Yupelri |
| Verity Pharmaceuticals INC. | $116.39 | 2025 | Tlando |
| Idorsia Pharmaceuticals US INC | $108.37 | 2022-2023 | Quviviq |
| Arbor Pharmaceuticals, INC. | $108.31 | 2020-2021 | |
| Eisai INC. | $99.03 | 2020-2021 | |
| Halozyme INC | $96.68 | 2023 | |
| Esperion Therapeutics, INC. | $84.01 | 2021-2023 | Nexletol |
| Teva Pharmaceuticals USA, INC. | $81.60 | 2019-2022 | |
| Kowa Pharmaceuticals America, INC. | $68.86 | 2019-2025 | Zoryve |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $67.35 | 2022-2023 | |
| Xeris Pharmaceuticals, INC. | $63.46 | 2025 | Recorlev |
| Phathom Pharmaceuticals, INC. | $63.31 | 2024-2025 | Voquezna |
| Abbott Laboratories | $61.56 | 2019-2025 | Freestyle Libre 3 |
| Medtronic, INC. | $52.71 | 2023 | Kyphon Express II Kyphopak Tray, Intellis Adaptivestim |
| Ironwood Pharmaceuticals, INC | $50.27 | 2020-2022 | |
| Daiichi Sankyo INC. | $49.95 | 2024 | Injectafer |
| Ardelyx, INC. | $48.43 | 2023-2024 | Ibsrela |
| Shield Therapeutics INC | $48.27 | 2024-2025 | |
| Mimedx Group, INC. | $47.50 | 2024-2025 | |
| Mannkind Corporation | $46.01 | 2025 | |
| Novartis Pharmaceuticals Corporation | $44.55 | 2019-2024 | |
| Optos, INC. | $42.11 | 2021-2022 | |
| Jazz Pharmaceuticals INC. | $39.71 | 2020-2022 | |
| Organon LLC | $37.40 | 2022-2023 | Nexplanon |
| Horizon Therapeutics Plc | $36.49 | 2019-2021 | |
| Abiomed | $35.00 | 2024 | Impella |
| Exact Sciences Corporation | $28.78 | 2024 | Cologuard Collection Kit |
| Recordati_rare_diseases_inc. | $25.89 | 2025 | Isturisa |
| Roche Diagnostics Corporation | $22.66 | 2021 | |
| Genentech USA, INC. | $20.52 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $20.47 | 2022 | |
| Baxter Healthcare | $20.34 | 2024 | Hillrom - Monarch Airway Clearance System |
| Sumitomo Pharma America, INC. | $19.22 | 2023 | Gemtesa |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $16.46 | 2019 | |
| Hologic Sales and Service, LLC | $16.41 | 2020 | |
| Coopersurgical, INC. | $15.90 | 2024 | Paragard T 380a |
| Medline Industries LP | $15.46 | 2019 | |
| Vbi Vaccine (Delaware) INC. | $15.39 | 2022 | |
| Nalu Medical, INC. | $15.05 | 2025 | Nalu Neurostimulation System |
| Aimmune Therapeutics, INC. | $14.03 | 2024 | |
| Therapeuticsmd, INC. | $13.80 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Holvik listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.